Coumarins

vitamin K epoxide reductase complex subunit 1 ; Homo sapiens







16 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 29218011 Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol. 2017 1
2 26314757 Comparative inhibitory effect of prenylated coumarins, ferulenol and ferprenin, contained in the 'poisonous chemotype' of Ferula communis on mammal liver microsomal VKORC1 activity. 2015 Oct 1
3 21469766 Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics. 2011 Feb 1 2
4 21651319 Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. 2011 Nov 2
5 20121287 Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. 2010 Feb 1 2
6 20205664 Pharmacogenetics of oral anticoagulant therapy. 2010 2
7 20585445 A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. 2010 Jun 18 1
8 19397481 Pharmacogenetics of vitamin K antagonists: useful or hype? 2009 2
9 19738376 Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients. 2009 1
10 19799531 Implications of pharmacogenetics for oral anticoagulants metabolism. 2009 Jul 1
11 22461099 Pharmacogenetics of cardiovascular drug therapy. 2009 Jan 1
12 18278162 [New insight in therapeutic anticoagulation by Coumarin derivatives]. 2008 Feb 1
13 18805772 [Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy]. 2008 Sep 28 2
14 17635701 VKORC1: molecular target of coumarins. 2007 Jul 2
15 17849045 Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. 2007 Sep 1
16 16879214 Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. 2006 Aug 2